Business briefs: Endo; Allergan

Share this article:

Endo, which has been reportedly on the hunt for a buyer, named former Valeant president Rajiv De Silva president and CEO, effective March 18. The company's C-Suite shakeup has given a boost to its stock price, which hit its highest point since January 30, reported Bloomberg.

Allergan has settled a Botox-related lawsuit in Oklahoma  for an undisclosed amount, according to Bloomberg. The company was sued by the mother of a teenager who claimed the treatment, used for a leg condition, in this case, led to his death. She also alleged Allergan “promoted the drug for children despite a lack of regulatory approval for such use." This is not the first time the company has been accused of marketing the drug for unapproved uses—as Pharmalot noted in June, the company paid $600 million three years ago for off-label promotion.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.